China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People's Republic of China. It offers products in the form of dry powder injectibles, liquid injectibles, tablets, capsules, oral solutions, and granules. The company's products are used for the treatment of central nervous system and cerebral cardiovascular, anti-infection and respiratory, and digestive and other diseases. Its products include Bumetanide to treat edema diseases; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Buflomedil Hydrochloride for blood vessel diseases; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and surgery-thrombus deep phlebitis; and Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and lipoprotein blood diseases. The company also provides Cefaclor Dispersible tablets for tympanitis, lower respiratory tract infection; Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Clarithromycin granules and capsules for nasopharynx, respiratory tract, and skin tissue infections; Naproxen Sodium and Pseudophedrine Hydrochloride Sustained Release tablets to relieve cold, sinus, and flu symptoms; Cefalexin capsules for acute tonsillitis; and Anhydroandrographolide for ischemic heart, cerebrovascular, and lipoprotein blood diseases. In addition, it offers Hepatocyte growth-promoting factor; Tiopronin; Omeprazole; Granisetron Hydrochloride injection; Vitamin B6; and Gull Wood extract syrup, as well as Recombined Human Fibroblast Growth Factor products for the repair of wounded skin cells. The company distributes its products through independent regional distributors and sales representatives. China Pharma Holdings, Inc. is based in Haikou, the People's Republic of China.